tetano
Editor, Senior Moderator
Int J Mol Sci
. 2020 May 28;21(11):E3843.
doi: 10.3390/ijms21113843.
Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
Xinling Wang[SUP] 1 [/SUP], Shuai Xia[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Wei Xu[SUP] 1 [/SUP], Weihua Li[SUP] 2 [/SUP], Lu Lu[SUP] 1 [/SUP], Shibo Jiang[SUP] 1 2 [/SUP]
Affiliations
Abstract
In the past 17 years, three novel coronaviruses have caused severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the coronavirus disease 2019 (COVID-19). As emerging infectious diseases, they were characterized by their novel pathogens and transmissibility without available clinical drugs or vaccines. This is especially true for the newly identified COVID-19 caused by SARS coronavirus 2 (SARS-CoV-2) for which, to date, no specific antiviral drugs or vaccines have been approved. Similar to SARS and MERS, the lag time in the development of therapeutics is likely to take months to years. These facts call for the development of broad-spectrum anti-coronavirus drugs targeting a conserved target site. This review will systematically describe potential broad-spectrum coronavirus fusion inhibitors, including antibodies, protease inhibitors, and peptide fusion inhibitors, along with a discussion of their advantages and disadvantages.
Keywords: COVID-19; antibody; entry inhibitor; fusion inhibitor; peptide; protease inhibitor.
. 2020 May 28;21(11):E3843.
doi: 10.3390/ijms21113843.
Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
Xinling Wang[SUP] 1 [/SUP], Shuai Xia[SUP] 1 [/SUP], Qian Wang[SUP] 1 [/SUP], Wei Xu[SUP] 1 [/SUP], Weihua Li[SUP] 2 [/SUP], Lu Lu[SUP] 1 [/SUP], Shibo Jiang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32481690
- DOI: 10.3390/ijms21113843
Abstract
In the past 17 years, three novel coronaviruses have caused severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the coronavirus disease 2019 (COVID-19). As emerging infectious diseases, they were characterized by their novel pathogens and transmissibility without available clinical drugs or vaccines. This is especially true for the newly identified COVID-19 caused by SARS coronavirus 2 (SARS-CoV-2) for which, to date, no specific antiviral drugs or vaccines have been approved. Similar to SARS and MERS, the lag time in the development of therapeutics is likely to take months to years. These facts call for the development of broad-spectrum anti-coronavirus drugs targeting a conserved target site. This review will systematically describe potential broad-spectrum coronavirus fusion inhibitors, including antibodies, protease inhibitors, and peptide fusion inhibitors, along with a discussion of their advantages and disadvantages.
Keywords: COVID-19; antibody; entry inhibitor; fusion inhibitor; peptide; protease inhibitor.